08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV E2 In vitro studies solved the structure of the HCV E2 protein, which could aid HCV vaccine and drug design. X-ray crystal...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus CD81 In vitro studies suggest inhibiting the interaction between CD81 and influenza virus could help treat or prevent infection. In a human...
07:00 , Sep 5, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Transgenic, humanized mouse model of HCV infection Partially immunocompromised, humanized mice could be used as a model of HCV infection to help evaluate antiviral drug...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Immunocompetent, humanized mouse model for HCV infection An immunocompetent, humanized mouse model of HCV could help evaluate potential HCV entry inhibitors...
07:00 , Jun 16, 2011 |  BC Innovations  |  Cover Story

HCV's mighty mouse

The most widely used animal model of HCV infection requires transplanting human hepatocytes into immunodeficient mice. These mice are useful for testing antivirals, but the absence of an immune system makes the animals unsuitable for...
07:00 , May 12, 2011 |  BC Innovations  |  Cover Story

Making the most of the host

Although recent attention in the HCV space has focused on positive FDA panel recommendations for the protease inhibitors telaprevir and Victrelis boceprevir from Vertex Pharmaceuticals Inc. and Merck & Co. Inc. , respectively, 1 a...
08:00 , Feb 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Infectious disease HCV Occludin (OCLN); CD81 Cell culture studies in humans and in rodents identified OCLN as a viral entry...
07:00 , Apr 9, 2007 |  BioCentury  |  Tools & Techniques

Ins & outs of HCV

In a pair of studies, researchers have identified two potential therapeutic targets for hepatitis C virus. Both are related to host cells, which means they might raise fewer viral resistance issues, although experience with similar...
08:00 , Nov 2, 1998 |  BC Week In Review  |  Company News

Chiron other research news

CHIR and collaborators found that the CD81 receptor is potentially important for allowing HCV to infect cells. As reported in Science, the virus protein E2 binds to the major extracellular loop of the CD81 receptor...